1.8801  0 (0.01%)		04-25 16:00
Open: 1.77 High: 1.95 Volume: 67,604		Pre. Close: 1.88 Low: 1.77 Market Cap: 5(M)

Short term
Mid term
Targets	6-month :	2.45	1-year :	2.8
Resists	First :	2.1	Second :	2.4
Pivot price	1.96
Supports	First :	1.62	Second :	1.35
MAs	MA(5) :	1.9	MA(20) :	1.95
	MA(100) :	1.63	MA(250) :	1.79
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	24.5	D(3) :	25.5
RSI	RSI(14): 49
52-week	High :	3.04	Low :	1.21

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ SILO ] has closed above bottom band by 26.6%. Bollinger Bands are 19% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	1.95 - 1.96	1.96 - 1.97
Low:	1.75 - 1.76	1.76 - 1.77
Close:	1.87 - 1.88	1.88 - 1.89

Silo Pharma, Inc. operates as a developmental stage biopharmaceutical company. The company focuses on merging traditional therapeutics with psychedelic research for patients with depression, post-traumatic stress disorder, Alzheimer's, Parkinson's, and other rare neurological disorders. It has a scientific research agreement with the University of Maryland, The Regents of the University of California, and Columbia University. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is headquartered in Englewood Cliffs, New Jersey.

Tue, 23 Apr 2024
Silo Pharma reports promising SPC-15 study for PTSD therapy - Investing.com

Tue, 23 Apr 2024
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment - Yahoo Finance

Thu, 11 Apr 2024
Silo Pharma Advances Alzheimer's Disease Treatment with SPC-14 - The Dales Report

Wed, 10 Apr 2024
Silo Pharma set to acquire licensing for Alzheimer's disease therapeutic (NASDAQ:SILO) - Seeking Alpha

Wed, 10 Apr 2024
Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer's Disease Therapeutic - Yahoo Finance

Tue, 02 Apr 2024
Silo Pharma And 3 Other Stocks Under $5 Insiders Are Buying - Alzamend Neuro (NASDAQ:ALZN), Anitra (AMEX: - Benzinga

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: PNK
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	3 (M)
Held by Insiders	2.54e+006 (%)
Held by Institutions	6.3 (%)
Shares Short	49 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	-5 %
Return on Assets (ttm)	347.4 %
Return on Equity (ttm)	-24.9 %
Qtrly Rev. Growth	72100 %
Gross Profit (p.s.)	0
Sales Per Share	-32.58
EBITDA (p.s.)	0
Qtrly Earnings Growth	-1.2 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-3 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	-0.06
Price to Cash Flow	1.19

Dividend	0
Forward Dividend	61390
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.